This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of
nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF
1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of
patients with unresectable malignant pleural mesothelioma.